stockportfolio.pro
Stocks / EPRX vs OCGN
EPRX vs OCGN
Eupraxia Pharmaceuticals Inc. and Ocugen, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Eupraxia Pharmaceuticals Inc. (EPRX) | Ocugen, Inc. (OCGN) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $0 | $4.41M |
| Net income (latest FY) | $-38.58M | $-67.85M |
| Revenue growth (5y CAGR) | — | 152.5% |
| Net margin | — | -1537.4% |
| Return on equity | -47.0% | 557.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EPRX — free Open OCGN — freeFrequently asked questions
Which is bigger, EPRX or OCGN?
Ocugen, Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, EPRX or OCGN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.